UA120529U - METHOD OF PRESERVATION OF KIDNEY FUNCTION IN PATIENTS WITH GHOST AND METABOLIC SYNDROME - Google Patents

METHOD OF PRESERVATION OF KIDNEY FUNCTION IN PATIENTS WITH GHOST AND METABOLIC SYNDROME

Info

Publication number
UA120529U
UA120529U UAU201703986U UAU201703986U UA120529U UA 120529 U UA120529 U UA 120529U UA U201703986 U UAU201703986 U UA U201703986U UA U201703986 U UAU201703986 U UA U201703986U UA 120529 U UA120529 U UA 120529U
Authority
UA
Ukraine
Prior art keywords
patients
metabolic syndrome
kidney function
ghost
preservation
Prior art date
Application number
UAU201703986U
Other languages
Ukrainian (uk)
Inventor
Олена Олександрівна Якименко
Марія Володимирівна Гриценко
Вікторія Валеріївна Тбілєлі
Original Assignee
Одеський Національний Медичний Університет
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Одеський Національний Медичний Університет filed Critical Одеський Національний Медичний Університет
Priority to UAU201703986U priority Critical patent/UA120529U/en
Publication of UA120529U publication Critical patent/UA120529U/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Спосіб збереження функції нирок у хворих, що страждають на подагру і метаболічний синдром, шляхом застосування препарату на основі низьких доз колхіцину та біофлавоноїду. На тлі стандартної медикаментозної антигіперурикемічної, протизапальної, гіполіпідемічної терапії призначають препарат на основі низьких доз колхіцину - Хомвіо-ревман по 10 крапель 2 рази на добу та біофлавоноїд Квертин 40 мг по 1 табл. 2 рази на добу протягом 6 місяців, з повторенням курсу через 2-3 місяці.A method of preserving kidney function in patients with gout and metabolic syndrome by administering a drug based on low doses of colchicine and bioflavonoid. Against the background of standard medication antihyperuricemic, anti-inflammatory, lipid-lowering therapy prescribe a drug based on low doses of colchicine - Homvio-rheuman 10 drops 2 times a day and bioflavonoid Quertin 40 mg per 1 table. 2 times a day for 6 months, with a repetition of the course after 2-3 months.

UAU201703986U 2017-04-24 2017-04-24 METHOD OF PRESERVATION OF KIDNEY FUNCTION IN PATIENTS WITH GHOST AND METABOLIC SYNDROME UA120529U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU201703986U UA120529U (en) 2017-04-24 2017-04-24 METHOD OF PRESERVATION OF KIDNEY FUNCTION IN PATIENTS WITH GHOST AND METABOLIC SYNDROME

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU201703986U UA120529U (en) 2017-04-24 2017-04-24 METHOD OF PRESERVATION OF KIDNEY FUNCTION IN PATIENTS WITH GHOST AND METABOLIC SYNDROME

Publications (1)

Publication Number Publication Date
UA120529U true UA120529U (en) 2017-11-10

Family

ID=60258640

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU201703986U UA120529U (en) 2017-04-24 2017-04-24 METHOD OF PRESERVATION OF KIDNEY FUNCTION IN PATIENTS WITH GHOST AND METABOLIC SYNDROME

Country Status (1)

Country Link
UA (1) UA120529U (en)

Similar Documents

Publication Publication Date Title
DOP2018000297A (en) DERIVATIVE OF GLUCAGON, CONJUGATE OF THE SAME, COMPOSITION THAT INCLUDES THE SAME AND THERAPEUTIC USE OF THE SAME
MX2020007625A (en) Mtor inhibitor, pharmaceutical composition and use thereof.
EA201001244A1 (en) SYSTEM OF DELIVERY OF MEDICINES WITH STABILIZING EFFECT
DK1883387T3 (en) Container for liquid drugs to be administered
JP2017502074A5 (en)
MX2018012800A (en) Administration of berberine metabolites.
FI2683245T4 (en) Methods and compositions for treating depression using cyclobenzaprine
UA120529U (en) METHOD OF PRESERVATION OF KIDNEY FUNCTION IN PATIENTS WITH GHOST AND METABOLIC SYNDROME
RU2015122833A (en) METHOD FOR TREATING CHRONIC ENDOMETRITIS
Myburgh et al. QUOTE
MX2018007377A (en) Hyaluronic acid composition for penile injections.
UA115757C2 (en) METHOD OF PRESERVATION OF KIDNEY FUNCTION IN PATIENTS WITH GHOST AND METABOLIC SYNDROME
BR112018009476A8 (en) plasminogen dosage regimen for wound healing
MX2018011293A (en) Prolonged release pharmaceutical composition comprising cysteamine or salt thereof.
CL2018003707A1 (en) Dosing regimens of vortioxetine for the rapid onset of the antidepressant effect.
UA145320U (en) METHOD OF INCREASING THE RESISTANCE OF THE BODY TO THE INFLUENCE OF HYPOXIA IN ELDERLY PEOPLE WITH METABOLIC SYNDROME
IT201700002235A1 (en) Composition for oral administration useful in the treatment of diabetes and metabolic syndrome in general
MX2020013385A (en) Methods of modulating tetrabenazine metabolites plasma levels using bupropion.
UA115803U (en) METHOD OF TREATMENT OF VERTEBROGENIC RADICULOPATHIES
UA130145U (en) METHOD OF CORRECTION OF ANEMIC SYNDROME IN SPORTS HORSES
UA115711U (en) METHOD OF TREATMENT OF Hepatic Encephalopathy in Patients with Secondary Biliary Cirrhosis of the Liver
UA104582U (en) A method for treating uncomplicated varicose veins
UA117785U (en) METHOD OF TREATMENT OF POLYCYSTOSIS OVERSYNDIC SYNDROME IN WOMEN WITH INSULIN RESISTANCE
MX2017001192A (en) Pharmaceutical composition of loratadine, phenylephrine, paracetamol and amantadine for oral administration, for the treatment of allopathies related to a common cold.
UA103788U (en) Method for treatment of acute coronary syndrome without st-segment elevation in patients with ischemic heart disease and metabolic syndrome following percutaneous transluminar coronary angioplasty